Looking to Register?
Sign Up Here

Haven't Received Your Link to the Virtual Platform?

Discover Tailored Services & Solutions For You

Welcome to the 3rd Annual Neuroimmunology Drug Development Summit:
Translate Key Technological & Mechanistic Neuroimmunology Advances into the Clinic

Translate Your Research Into the Clinic

The 3rd Neuroimmunology Drug Development Summit is the industry’s definitive and unrivalled forum focused solely on pushing the frontiers of targeting neuroinflammation for CNS Indications.

As diverse programs are advancing towards the clinic, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology-targeted therapeutics.

Building on the success of last year’s meeting, this year’s program will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies.

Discuss the Translation of Therapeutic Efficacy in Neuroinflammation

As we gather the best minds in this infant field, we will put a spotlight on the latest key learnings across microglia, astrocytes, STING, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic.

We will discuss the translation of therapeutic efficacy in neuroinflammation and the importance of identifying the best biomarkers and relevant models to ensure clinical trial success.

Network and Forge Collaborations Within the Industry

Join this intimate, industry led forum to not only learn from those pioneering the field, but to network and build meaningful partnerships with over 80 neuroimmunology drug development experts.

Connect with your peers from the likes of Merck, Sanofi, Biogen, Alector, Denali, Roche, Janssen, Genentech and Lundbeck to establish new relationships within this niche community.

To find out more and view the full speaker line-up, download the 2021 event guide by following the link below.

World-Class Speakers Include:

Brad Friedman

Senior Scientist, Department of OMNI Bioinformatics

Genentech

Courtney Easley-Neal

Senior Scientist, In Vivo Biology & Imaging

EISAI

Pascal Sanchez

Director, Translational Sciences

Denali Therapeutics

Philip Kong

Associate Director Immuno-Neurology

Alector

Robert Baloh

VP, Global Head of Research in Neuroscience & Rare Diseases

pRED at Roche

Carlos Pedraza

Director of CNS Biology

Alkermes

Charlotte Callaghan

Chief Scientific Officer & Patient Insight Manager

Ulysses Neuroscience

Kristina Holmberg

Associate Director, Translational and Clinical Biomarkers

EMD Serono

Philip Ashton-Rickardt

Senior Vice President, Immunology

AZTherapies

Rebecca Coll

Principal Investigator, Lecturer in Immunobiology, Wellcome-Wolfson Institute for Experimental Medicine

Queen's University Belfast, UK

Reviews From the Neuroimmunology Community:

“Teriffic meeting and glad to have it on my radar” - Brett Adams, Vice President, Magnolia Neurosciences
t
"Very focused meeting, that accomplished a lot in two days. The presentations were high quality and organised into interesting sessions" - Sally Ishizaka, Senior Director, Eisai
t
'Excellent meeting! I learned a lot' - Gayathri Ramaswamy, Associate Director, Biogen

Sponsoring Partners:

Other Events in the World CNS Series: